Larimar Therapeutics公布的数据显示，其药物Nomlabofusp的长期给药方案在总体上表现出良好的耐受性。然而，在参与研究的43名患者中，有10例出现了过敏反应。这一发现凸显了在评估该疗法安全性时需持续关注的风险因素。
Larimar Therapeutics公布的数据显示，其药物Nomlabofusp的长期给药方案在总体上表现出良好的耐受性。然而，在参与研究的43名患者中，有10例出现了过敏反应。这一发现凸显了在评估该疗法安全性时需持续关注的风险因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.